#NARCancer
Epigenetic adaptations and vulnerabilities in ovarian cancer drug-tolerant persister cells academic.oup.com/narcancer/ar...
Epigenetic adaptations and vulnerabilities in ovarian cancer drug-tolerant persister cells
Abstract. High-grade serous ovarian carcinoma (HGSOC) recurs in most patients despite initial responses to chemotherapy and poly(ADP-ribose) polymerase inh
academic.oup.com
October 27, 2026 at 4:32 PM
narcancer
October 25, 2026 at 11:54 PM
⭐ How does the #BRCA network protect genome stability, and how can its vulnerabilities guide #cancertreatment? Explore 17 #NARCancer articles curated for the NAR Journals’ RRS session. #RadiationResearchSocietyMeeting #DNARepair @aibsbiology.bsky.social @nar-cancer-editor.bsky.social 1/18
October 7, 2026 at 1:44 AM
New tool in the breast cancer toolbox: eRNACare, a public web application for individualized survival and tumor probability scoring based on validated panels of enhancer RNAs. New in NAR Cancer. academic.oup.com/narcancer/ar...
Integrative multi-omics profiling and machine learning reveal enhancer RNA signatures for early detection and prognostic stratification in breast cancer
Abstract. Current breast cancer biomarkers rely predominantly on protein-coding transcriptomes, leaving the regulatory information encoded by enhancer RNAs
academic.oup.com
September 27, 2026 at 9:15 PM
From Bevin Engelward and colleagues: Spectacular study of NDMA liver carcinogenesis in mice shows persistent adducts, DNA damage response, interferon expression, immune cell infiltration, and clonal expansion promoting tumor emergence. Destined to be a classic! 2/3 academic.oup.com/narcancer/ar...
Persistent interferon signaling and clonal expansion mark early events in DNA methylation damage-induced liver cancer
Abstract. N-Nitrosodimethylamine (NDMA), a probable human carcinogen, induces toxic and mutagenic DNA O6-methylguanine (O6MeG) adducts that are repaired by
academic.oup.com
September 14, 2026 at 5:19 PM
From Dmitry Gordenin and colleagues: Half of tumor mutations may accumulate while precancer, but study is challenging. Analysis of 10,000 human samples identifies mutations arising from clock-like processes, deaminases, mutagens. Fundamental + practical insights. 3/3 academic.oup.com/narcancer/ar...
Motif-centered analyses reveal universal and tissue-specific mutagenic mechanisms operating in the human body
Abstract. Somatic mutations are inevitable in human genomes and can lead to cancer initiation and tumor progression. Although many mutagenic processes have
academic.oup.com
September 14, 2026 at 5:19 PM
Glioblastoma remains one of the most feared cancers. Here, in vivo-selected, shape-based DNA aptamers are used to replace the large antibodies used in conventional drug conjugates - unbiased approach to a problem that rational design has yet to overcome. academic.oup.com/narcancer/ar...
In vivo selection of anti-glioblastoma DNA aptamer-drug conjugates in an orthotopic patient-derived xenograft model
Abstract. Glioblastoma (GBM) is an aggressive, high-grade glioma with a near-universally fatal prognosis. Therapeutic failure is often attributed to the hi
academic.oup.com
September 5, 2026 at 12:22 PM
Ewing sarcoma tumor fitness depends on three snoRNA host genes–SNHG1, SNHG12, and SNHG30–that regulate chemical modification of ribosomal RNA. Blocking them slowed tumor growth, pointing to a strategy to target the unique EWS-FLI1 biology sustaining Ewing sarcoma. academic.oup.com/narcancer/ar...
SNHG family lncRNAs promote Ewing sarcoma cell fitness through intronic snoRNA-guided rRNA modifications
Abstract. Over 90% of Ewing sarcomas (EWS) are driven by the EWS–FLI1 fusion oncoprotein. EWS–FLI1 acts as a pioneer transcription factor, altering the exp
academic.oup.com
August 29, 2026 at 7:11 PM
The quest to identify genetic susceptibility to breast cancer continues - of 33 clinically identified RAD51C variants, several have intermediate homologous recombination deficiencies, and some have distinct therapeutic vulnerabilities. New in NAR Cancer: academic.oup.com/narcancer/ar...
RAD51C breast cancer-identified variants with attenuated homologous recombination function exhibit sensitivity to combined PARP1 and ATR inhibition
Abstract. The tumor suppressor RAD51C is essential for DNA double-strand break repair through the homologous recombination (HR) pathway. RAD51C loss is lin
academic.oup.com
August 22, 2026 at 5:52 PM
Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment academic.oup.com/narcancer/ar...
By fantastic Roderic Espin! And thanks to many, in particular Aytes & Vinyals teams!
@idibell.bsky.social IDIBGI ICO CERCA
Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment
Abstract. Alternative end-joining (alt-EJ) is an error-prone DNA repair pathway that cancer cells deficient in homologous recombination rely on, making the
academic.oup.com
March 8, 2025 at 10:08 PM
academic.oup.com/narcancer/ar.... Why do T-ALL patients relapse with chemo-resistant leukemia? Our new study in NAR Cancer finds cytarabine resistance leaves a distinct mutational signature, and chemo's mutagenic effects can be indirect: selecting mutator clones.🧬 @narjournal.bsky.social #leukemia
Validate User
academic.oup.com
August 21, 2026 at 5:05 PM
As a scientist, there are not many things more gratifying than to see my teams’ work directly involved in saving lives and @nanoporetech.com applied routinely in the clinic.
Big thanks to all the great team from Schneider Children’s Medical Center.

academic.oup.com/narcancer/ar...
Brain tumor classification from FFPE samples using nanopore methylation sequencing
Abstract. Oxford Nanopore Technology (ONT)-based methylation sequencing is emerging as a powerful approach for the rapid and accurate classification of bra
academic.oup.com
November 11, 2025 at 3:35 PM
Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment academic.oup.com/narcancer/ar... #hvhebron #onco [Text complet]
Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment
Abstract. Alternative end-joining (alt-EJ) is an error-prone DNA repair pathway that cancer cells deficient in homologous recombination rely on, making the
academic.oup.com
March 20, 2025 at 8:51 AM
5th Anniversary Thematic Collection: Manipulating DNA Repair and the DNA Damage Response to Improve Cancer Therapy url:https://academic.oup.com/narcancer/pages/manipulating-dna-repair @emgsus.bsky.social @weldeiry.bsky.social
March 5, 2026 at 9:03 PM
Great to see our latest study out in NAR Cancer: Replication-associated base excision repair/single-strand break repair regulates PARG inhibitor response via the PRMT1/PRMT5/ATR axis url: academic.oup.com/narcancer/ar... @weldeiry.bsky.social @emgsus.bsky.social
Replication-associated base excision repair/single-strand break repair regulates PARG inhibitor response via the PRMT1/PRMT5/ATR axis
Abstract. Poly(ADP-ribose) polymerases 1 and 2 (PARP1/PARP2), and poly(ADP-ribose) glycohydrolase (PARG), modulate the level of poly(ADP-ribose) (PAR), a p
academic.oup.com
December 31, 2025 at 5:16 PM
For all burgeoning cancer dark genome fanatics: Do you ever wonder what the evidence for upstream open reading frames in cancer is?

Thanks to Anwesha Dasgupta in my lab, we've synthesized the main points in this comprehensive review:
academic.oup.com/narcancer/ar...

🧪
🔎 microproteins
🖥️ + 🧬
academic.oup.com
May 23, 2024 at 1:05 PM
Calling the genome instability community!! This free symposium from NAR Cancer, courtesy @nar-cancer-editor.bsky.social looks fantastic! I just registered.

academic.oup.com/narcancer/pa...
NAR Cancer 5th Anniversary Virtual Symposium
NAR Cancer is pleased to partner with the high-visibility Social DNAing webinar series, hosted by Columbia University, to present their 5th anniversary virtual
academic.oup.com
December 6, 2024 at 2:44 AM
Published our research work in the NAR Cancer Journal;

DNA abasic sites act as rational therapeutic targets to synergize temozolomide response in both MMR-proficient and deficient cancer
academic.oup.com/narcancer/ar...
November 19, 2024 at 1:24 PM
😀Thrilled to have contributed to this study on SRSF2, which, when over expressed, drives replication-transcription conflicts and impacts DSB repair pathway choice! A step forward in understanding lung cancer progression! 🧬 academic.oup.com/narcancer/ar...
SRSF2 overexpression induces transcription-/replication-dependent DNA double-strand breaks and interferes with DNA repair pathways to promote lung tumor progression
Abstract. SRSF2 (serine/arginine-rich splicing factor 2) is a critical regulator of pre-messenger RNA splicing, which also plays noncanonical functions in
academic.oup.com
April 3, 2025 at 3:53 PM
NAR Cancer 2025 impact factor rises to 4.6; other metrics at journal home page. Appreciate our authors, reviewers, editors. Encourage submissions at intersection of cancer and nucleic acids fields–full info and details of forthcoming "Seeds of Cancer" collection at academic.oup.com/narcancer/pa...
Call for Papers
NAR Cancer is a peer-edited, not-for-profit, Open Access journal published by Oxford University Press. In seven years, it has established a reputation for high-
academic.oup.com
June 18, 2026 at 6:11 PM
PARP inhibitors work in BRCA-mutant cancers, but resistance is common. Buckley-Benbow et al. show loss of CHTF18-RFC2/5 sensitizes cells via replicative gaps (not recombination defects), and isn’t rescued by 53BP1 loss—highlighting new therapeutic targets. academic.oup.com/narcancer/ar...
Loss of CHTF18–RFC2/5 leads to replicative gaps and sensitivity to PARP inhibitors
Abstract. The use of PARP inhibitors (PARPi) has profoundly changed the treatment of BRCA1/BRCA2-mutated cancers. Despite this, acquired resistance to PARP
academic.oup.com
June 7, 2026 at 9:36 PM
Can SMC5/6 status help guide precision cancer therapy? A new NAR Cancer study links deleterious SMC5/6 variants to tumor mutational burden and immunotherapy responses, driven via POLE dysfunction and mismatch repair deficiency.https://academic.oup.com/narcancer/article/8/2/zcag012/8688771
Disruption of the structural maintenance of chromosomes 5/6 complex enables tumor mutagenesis
Abstract. The structural maintenance of chromosomes (SMC) 5/6 complex is conserved and essential for mammalian development. SMC5/6 germline variants in cel
academic.oup.com
May 27, 2026 at 12:07 AM
Few cancer driver mutations have been identified in promoters, maybe for technical reasons. New assay targets >3,000 promoters — hits in CDK4, SMAD3, and GATA3 in breast cancer provide promising leads for functional follow-up. academic.oup.com/narcancer/ar... #CancerGenomics #NonCoding #Promoters
Sensitive detection of somatic mutations in GC-rich cancer gene promoters
Abstract. Somatic mutations in protein-coding genes and noncoding regulatory regions are the major drivers of cancer. Only a relatively small number of som
academic.oup.com
May 7, 2026 at 6:42 PM